Table 2.
Fluoroquinolone resistance-associated mutations in M. genitalium-positive patients.
| All Patients | Cohort | ||
|---|---|---|---|
| Women | MSM | ||
| parC gene | |||
| Successful amplification | 338 | 276 | 62 |
| Wild type | 291 (86.1%) | 251 (90.9%) | 40 (64.5%) |
| Mutations detected a | 47 (13.9%) | 25 (9.1%) | 22 (35.5%) |
| Gly81Cys | 1 | 1 | - |
| Ser83Arg | 1 | 1 | - |
| Ser83Asn | 4 | 2 | 2 |
| Ser83Ile | 32 | 13 | 19 |
| Asp87Asn | 2 | 2 | - |
| Asp87Tyr | 3 | 3 | - |
| Ser95Asn | 1 | 1 | - |
| Ile105Phe | 1 | 1 | - |
| His106Tyr | 1 | 1 | - |
| Ala119Val | 1 | - | 1 |
| No amplification | 32 | 29 | 3 |
| Total of patients | 370 | 305 | 65 |
| gyrA gene | |||
| Successful amplification | 283 | 227 | 56 |
| Wild type | 279 (98.6%) | 225 (99.1%) | 54 (96.4%) |
| Mutations detected | 4 (1.4%) | 2 (0.9%) | 2 (3.6%) |
| Gly93Cys b | 1 | - | 1 |
| Met95Ile b | 1 | - | 1 |
| Ala105Thr | 1 | 1 | - |
| Asp107Asn | 1 | 1 | - |
| No amplification | 55 | 49 | 6 |
| Total of patients | 338 | 276 | 62 |
aM. genitalium numbering. b gyrA mutations associated with the Ser83Ile parC mutation. Mutations likely of clinical significance are noted in bold. gyrA PCR was performed only on samples with successful parC amplification.